We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue. Learn more OK
Roche Australia Menu Search : Tecentriq Roche Australia

You are here:

  1. What we do
  2. Pharmaceuticals
  3. Tecentriq
  • Home
  • Roche in Australia
  • What we do
  • Sustainability
  • Our innovation
  • Supporting patients
  • Healthcare Professionals
  • News & Publications
  • Perspectives
  • Working at Roche
  • Contact

Pharmaceutical Product Information

Tecentriq® (atezolizumab)

Roche update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer - IMpassion131 results.

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

 

Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close

View all products

Patient site

The following website is only intended for Australian patients who have been prescribed the relevant medicine or test, and requires a login or activation code to access. Patients should discuss any questions they have on accessing these sites with their healthcare professional.

www.tecentriq.com.au

  • © 2020 Roche Australia
  • 15.10.2020
  • Privacy Policy
  • Terms of Use
  • Terms of Sale
  • Contact Us
  • Whistleblowing

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report an adverse event (side effect) associated with a Roche medicinal product, please contact the Roche Australia Drug Safety Department immediately on [email protected] or on +61 (0)2 9454 9444.

  • Find us on LinkedIn